Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 2/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25878282 | 0.76 | CYP4F2 (0.33) | NR3C1NR3C2MEN1KMT2A | |
| SCHEMBL25877362 | 0.73 | TTR (0.30) | — | |
| SCHEMBL11811006 | 0.66 | MEN1 (0.41) | MEN1KMT2AALDH1A1POLBHPGD | |
| SCHEMBL1818682 | 0.63 | CYP2A6 (0.50) | MEN1KMT2AALDH1A1POLBHPGD | |
| SCHEMBL29953142 | 0.63 | CYP2A6 (0.50) | MEN1KMT2AALDH1A1POLBHPGD | |
| SCHEMBL29956213 | 0.62 | CYP2A6 (0.48) | MEN1KMT2AALDH1A1POLBHPGD | |
| SCHEMBL16632464 | 0.60 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL11594562 | 0.60 | ALDH1A1 (0.57) | MEN1KMT2AALDH1A1POLBHPGD | |
| SCHEMBL31749884 | 0.59 | KIF11 (0.33) | ALDH1A1 | |
| SCHEMBL17310947 | 0.59 | CYP1A2 (0.56) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234965-A1 | N-LINKED MACROCYCLIC 4-(PYRAZOL-5-YL)-INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234965-A1 | N-LINKED MACROCYCLIC 4-(PYRAZOL-5-YL)-INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | MCL1, BCL2L1, BAK1 | NR3C1 2030/4885NR3C2 3898/4885MEN1 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.